GSK (LSE:GSK) recently announced the FDA approval of Blujepa, a first-in-class antibiotic for urinary tract infections, and ...

GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of oral antibiotics for the condition in nearly 30 years. Blujepa ...

The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...

Blujepa marks the first new oral antibiotic to gain FDA approval for uncomplicated urinary tract infections in nearly 30 years. The FDA has approved GSK’s Blujepa (gepotidacin), a first-in-class oral ...

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

A pill developed by GSK was found to be safe and effective in treating gonorrhea in a late-stage clinical trial, according to ...

GSK's Blujepa met primary endpoints in phase 3 trials, showing 58.5% success in EAGLE-3 vs. 43.6% for nitrofurantoin in uUTI treatment. The FDA approved Blujepa for uUTIs in female adults and ...